Efficacy and safety of pravastatin in patients with primary hypercholesterolemia
| Autor: | John B. Kostis, Margot J. Mellies, Henry Y. Pan, Donald B. Hunninghake, Anne C. Goldberg, Helmut G. Schrott, Peter T. Kuo, William Insull |
|---|---|
| Rok vydání: | 1990 |
| Předmět: |
Chemotherapy
medicine.medical_specialty Evening biology Cholesterol business.industry medicine.medical_treatment nutritional and metabolic diseases Pharmacology Gastroenterology Clinical trial chemistry.chemical_compound chemistry Internal medicine HMG-CoA reductase medicine biology.protein lipids (amino acids peptides and proteins) Cardiology and Cardiovascular Medicine business Pravastatin Morning Lipoprotein medicine.drug |
| Zdroj: | Atherosclerosis. 85:219-227 |
| ISSN: | 0021-9150 |
| DOI: | 10.1016/0021-9150(90)90114-x |
| Popis: | This 8-week multicenter, placebo-controlled trial compared. the efficacy and safety of the HMG-CoA reductase inhibitor, pravastatin, when administered either as single doses of 40 mg in the morning (AM) or evening (PM) or 20 mg twice daily (bid) in 196 diet-stabilized outpatients with primary type II hypercholesterolemia. Mean reductions in total and low-density lipoprotein (LDL) cholesterol concentrations were observed in all pravastatin groups after 1 week and were sustained throughout the study (P |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|